Hepatocellular Carcinoma Resectable clinical trials

Explore recruiting hepatocellular carcinoma resectable clinical trials.

Recruiting hepatocellular carcinoma resectable studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatocellular Carcinoma Resectable trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase II, randomized, open-label, national, multicenter study evaluating the efficacy and safety of the combination of atezolizumab and bevacizumab as neoadjuvant plus adjuvant treatment in hepatocellular carcinoma (ASPIRE)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

PHITT: Paediatric Hepatic International Tumour Trial

Poland, Germany, France, Belgium, Ireland, Spain +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hepatocellular Carcinoma Resectable trials by city

Hepatocellular Carcinoma Resectable clinical trials

Recruiting hepatocellular carcinoma resectable studies right now

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy

Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma

Also recruiting in Europe

A phase II, randomized, open-label, national, multicenter study evaluating the efficacy and safety of the combination of atezolizumab and bevacizumab as neoadjuvant plus adjuvant treatment in hepatocellular carcinoma (ASPIRE)

PHITT: Paediatric Hepatic International Tumour Trial

Hepatocellular Carcinoma Resectable trials by city

Other conditions